US Edition
News from bariatricnews.net
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top bariatricnews.net News
Health & Medicine · United KingdomThe weight loss jabs Mounjaro and Wegovy may need to be continued for life to keep obesity under control, new research suggests. The finding will dismay people who are stretching their household finances to afford treatment, which can cost up to £300 a month depending on the dose and drug.See the Story
Less than two years after stopping obesity drugs, weight and health issues return, study finds
49% Center coverage: 70 sources
GLP-1 · United KingdomIn early 2025, around 4.9 million British adults - almost one in ten - are estimated to have recently used, or expressed interest in using, glucagon-like peptide-1 (GLP-1) or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist medications to support weight loss. The findings, which are based on a nationally representative household survey of 5,260 British adults, are published in BMC Medicine.See the Story
Study highlights prevalence of GLP-1/GIP medication use for weight loss in UK
Coverage: 2 sources
United Kingdom · United KingdomPeople prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss, say experts at UCL and the University of Cambridge.See the Story
Weight Loss Drugs May Cause Nutritional Deficiencies without Proper Guidance
Coverage: 2 sources
